Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

rPCI-24781 is an orally-bioavailable histone deacetylase inhibitor that is in multiple clinical trials. We are conducting a Phase I trial in patients with advanced solid tumors, a Phase I/II trial in sarcoma patients (in combination with doxorubicin, an anti tumor agent) and a Phase I/II trial  testing PCI-24781 in patients with relapsed or refractory Non-Hodgkin's lymphoma. Currently we are enrolling the final follicular lymphoma patients in the Phase II portion of this trial and expect to complete enrollment by Q4 of calendar 2011.  Our collaboration partner for ex-US development, Servier, has five Phase I and I/II trials ongoing in Europe in lymphomas and solid tumors.

Conference Call and Webcast DetailsThe Company will hold a conference call today at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-407-8133 for domestic callers and 1-201-689-8040 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

For further questions please contact Ramses Erdtmann, VP Finance at: 408-215-3325

Non-Hodgkin's Lymphoma (NHL) Market There are significant and distinct areas of unmet medical need across the NHL subtypes.  Within the indolent lymphomas, we believe a need exists for active therapies that avoid the toxicities typically seen with conventional chemotherapies. Such active therapies are needed as part of effective combinations early in the course of treatment, and also as effective single-agent treatments later in the course of disease progression.  In particular, drugs which are well tolerated and which do not limit subsequent treatment options b
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... 27 454 Life Sciences, a Roche,company, ... of Illinois,at Urbana-Champaign today announced that they ... wasps. Using the company,s Genome,Sequencer(TM) system, the ... wasps and correlated different expression patterns to ...
... Investigations," Says ... Dissenting Panel Member, ATLANTA, ... the relationship between mercury (thimerosal) in vaccines and,children,s brain functioning ... Sallie Bernard, Executive Director of,SafeMinds. "Early Thimerosal Exposure and ...
Cached Medicine Technology:454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps 2454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps 3Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds 2
(Date:7/11/2014)... Thompson HealthDay Reporter THURSDAY, ... with HIV who was thought to be cured by immediate ... detectable levels of the AIDS-causing virus in her bloodstream, disappointed ... 4 years old, had remained virus-free even though she stopped ... had hoped her remission would open the door to a ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The Europe Well ... market in Europe with analysis and revenue forecast. The well ... around $2.4 billion in 2013 to $3.4 billion by 2018, ... Browse through the TOC of the Europe Well Intervention Market ... This also provides a glimpse of the segmentation in the ...
(Date:7/11/2014)... News) -- Children who have emergency surgery on ... potentially even death than those who have weekday ... the Johns Hopkins researchers noted that the risk ... data on nearly 440,000 simple emergency surgeries that ... 22-year period. The surgeries are considered generally ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... PROVIDENCE, R.I. -- Researchers from The Miriam ... under age 65 have significantly higher rates of ... with mobility impairments were less likely to attempt ... quit-smoking treatments may not be sufficient for this ... online in advance of print in the ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2
... The Libyan Department of Relief and Humanitarian ... a significant capability for medical disaster response in ... experts from the American-based company BLU-MED Response Systems ... University where members of Libyan Aid erected the ...
... March 3 Sysmex America, Inc., a leading ... today announced the availability of the Sysmex WAM ... middleware user facilities across the U.S. Sysmex WAM ... tool for new Sysmex WAM users and as ...
... soles of their feet and the palms of their hands ... some types of chemotherapy. Patients, family members also can feel ... Both share a need for quick answers or more detailed ... or unexpected symptoms. , A new section of the ...
... Oxygen Community Welcomes New Leaders Known for Patient Advocacy, ... The Council for Quality Respiratory Care (CQRC), an alliance ... care for nearly one half of the 1.5 million ... for improved quality of life, today praised President Obama,s ...
... FRANKLIN, Mass., March 3 PLC Systems Inc. (OTC Bulletin ... the news wire its financial results for the fourth quarter ... on Thursday, March 12, 2009. The company plans to host ... ET on that same day. The call may be joined ...
... as Possible , ALEXANDRIA, Va., March 3 The ... to know that hospice delivers the highest quality care ... coping with life-limiting illness. A recent article carried by ... Greg Bluestein, 03/02/09) carries a misinformed quote from an ...
Cached Medicine News:Health News:Libyan Aid Tests 50-Bed BLU-MED Deployable Field Hospital 2Health News:Sysmex America Introduces On Demand Middleware Training Tool 2Health News:Walther Cancer Foundation grant funds new IU Simon Cancer Center Web site section 2Health News:Council for Quality Respiratory Care Applauds President Obama's Appointments of Governor Sebelius, DeParle to Lead Health Care Efforts 2Health News:NHPCO Comments on Misleading Quote in Associated Press Article and Provides Helpful Information 2
... from Medtronic is changing the way clinicians ... their Medtronic CareLink Monitor and a standard ... information from their home or while traveling. ... have the ability to review device data ...
... Innova 3100 lets you perform exams from ... one room. With no compromises. An ideal ... a wide range of cardiovascular and interventional ... suited for a variety of vascular and ...
... Service provides clinically valuable, device-derived information ... failure to help specialty physicians discern ... are stable or deteriorating. For example, ... a Medtronic InSync Sentry™ CRT-D system ...
... Arginine vasopressin (AVP), also known as Antidiurectic ... and is transported via exonal flow to ... release. AVP secretion is regulated by changes ... that respond to alterations in blood volume ...
Medicine Products: